IVERIC bio, Inc. ISEE
Set alert
At close · Jul 10
52-week range unavailable
- Open
- 39.86
- Prev close
- 39.95
- Mkt cap
- 5.51B
- Vol
- 10.80M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 39.85
- High
- 39.98
- Forward P/E
- -26.99
- Beta
- 1.10
- Short ratio
- 5.25
- Inst. own
- 109.36%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 25, 2023
- 50-d avg
- 38.32
- 200-d avg
- 26.70
- 1y target
- 38.50
News
1 week ago gurufocus.com
Fujitsu, Nagoya University, JAMSTEC and NICT develop technology to automatically optimize parameters for solar energetic particle simulations
Helping protect astronauts from radiation risks while promoting the use of satellite data and the creation of future lunar industriesKawasaki, Nagoya, Yokosuka
3 years ago prnewswire.com
Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)
GA is a form of age-related macular degeneration (AMD) that causes irreversible vision loss, affecting approximately 1.5 million people in the United States 1,2 Eric and his mother, Jamey, are…
3 years ago prnewswire.com
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
GATHER2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham IZERVAY 24-month safety data were consistent with 12-month…
3 years ago prnewswire.com
European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy
TOKYO , Aug. 18, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the European Medicines Agency (EMA) has accepted for regulatory…
3 years ago prnewswire.com
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
IZERVAY is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials IZERVAY slowed…
3 years ago gurufocus.com
Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc
Deep Track Capital, LP (Trades, Portfolio), a prominent investment firm, recently made a significant move in the stock market by acquiring a new stake in Terns Pharmaceuticals Inc. This article will…
3 years ago prnewswire.com
Astellas Completes Acquisition of Iveric Bio
TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the…
-
3 years ago benzinga.com
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as…
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
3 years ago headlinesoftoday.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ISEE, MDWT, RXDX, UNVR
NEW YORK, May 1, 2023 /PRNewswire/ — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of…
3 years ago proactiveinvestors.com
Iveric Bio stock surges on Astellas Pharma takeover deal
Iveric Bio Inc shares climbed 16% to $38.01 on Monday after the US drugmaker agreed to be acquired by Japan's Astellas Pharma for $40 per share in cash or total consideration of about $5.9 billion.…
3 years ago investors.com
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
Astellas Pharma snapped up Iveric Bio for $5.9 billion in cash, the companies said Monday in an announcement that sent ISEE stock flying. The post Biotech Buying Bonanza: Iveric Bio Snags $5.9…
-
3 years ago benzinga.com
IVERIC bio, Ascendis Pharma And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Apollomics, Inc. (NASDAQ: APLM) surged 58.4% to $7.35 in pre-market…
3 years ago barrons.com
Iveric Bio Stock Surges. It's Being Bought by Astellas for $5.9 Billion.
Japan's Astellas agrees to pay $40 a share for Iveric, citing the potential of the biopharmaceutical company's ophthalmology programs.
3 years ago marketwatch.com
Japan's Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion
Astellas Pharma Inc. said Monday that it agreed to acquire Iveric bio Inc. for about $5.9 billion to strengthen its capabilities in the ophthalmology field.
-
3 years ago benzinga.com
Top 5 Health Care Stocks That May Fall Off A Cliff This Quarter
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
-
3 years ago benzinga.com
Why Heska Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Nogin, Inc. (NASDAQ: NOGN) shares surged 172.4% to $7.41. Guardforce AI Co., Limited (NASDAQ: GFAI) jumped 101% to $14.24 after climbing 50% on Friday.
3 years ago 247wallst.com
These Are the Top 10 Holdings of David Kim
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec…
-
3 years ago benzinga.com
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
-
3 years ago benzinga.com
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
-
3 years ago benzinga.com
Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program.
-
3 years ago benzinga.com
AutoNation, HubSpot, AMC Networks And Other Big Stocks Moving Higher On Friday
U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Friday. Here are some big stocks recording gains in today’s session.
-
3 years ago benzinga.com
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday
Gainers AGBA Group Holding Limited (NASDAQ: AGBA) gained 50.7% to close at $6.78 on Friday.
3 years ago investorplace.com
Why Is Iveric Bio (ISEE) Stock Up 25% Today?
Against a relatively flat backdrop for the major equity indices, biotechnology firm Iveric Bio (NASDAQ: ISEE ) provided a decisively positive framework, with shares gaining 25% on Friday afternoon.…
3 years ago seekingalpha.com
IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript
IVERIC bio, Inc. (NASDAQ:ISEE ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Kathy Galante - SVP, IR & Corporate Communications Glenn Sblendorio - CEO & Director…
3 years ago businesswire.com
Iveric Bio to Present at Upcoming Investor Conferences
PARSIPPANY, N.J.
3 years ago investors.com
Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio
Apellis reported an unexpected delay for its eye-disease treatment, leading APLS stock to crash as shares of rival Iveric Bio inched higher. The post Apellis Pharma Crashes On Unexpected Delay For…
4 years ago businesswire.com
Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the third quarter ended September 30, 2022 and provided a general business…
-
4 years ago benzinga.com
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
4 years ago 247wallst.com
These Were The Five Best And Worst Performing Mid-Cap Stocks In September 2022
Mid-cap stocks are a good choice for investors who are okay with relatively more volatility to get some extra returns.
4 years ago businesswire.com
Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio will present top-line efficacy and safety results from GATHER2, the Company's second Phase 3 clinical trial of Zimura, at AAO 2022.
-
4 years ago benzinga.com
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to…
-
4 years ago benzinga.com
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
-
4 years ago benzinga.com
Why HyreCar Is Trading Higher By 60%, Here Are 63 Stocks Moving In Tuesday's Mid-Day Session
Gainers HyreCar Inc. (NASDAQ: HYRE) jumped 60% to $1.2680 after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist…
-
4 years ago benzinga.com
US Stocks Trade Lower; Dow Drops Over 100 points
U.S. stocks traded lower this morning, with the Dow Jones dropping over 100 points on Tuesday. All the three major indices recorded their third weekly loss in a row, with the Dow dropping around 3%,…
-
4 years ago benzinga.com
Why Several Chinese Stocks Traded Higher; Here Are 58 Biggest Movers From Yesterday
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) surged 95.3% to close at $0.2580 on Thursday after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and announced a price target…
-
4 years ago benzinga.com
Earnings Scheduled For July 26, 2022
Companies Reporting Before The Bell • General Motors (NYSE:GM) is likely to report quarterly earnings at $1.30 per share on revenue of $34.59 billion.
-
4 years ago benzinga.com
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
-
4 years ago benzinga.com
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
-
4 years ago benzinga.com
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
During Tuesday's morning session, 95 companies made new 52-week highs.
-
5 years ago benzinga.com
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET on Friday, 115 companies hit new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
During Tuesday's morning session, 124 stocks hit new 52-week highs.
-
5 years ago benzinga.com
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.
-
5 years ago benzinga.com
Earnings Scheduled For March 3, 2021
Companies Reporting Before The Bell • Brown Forman Inc Class A Common Stock (NYSE:BF) is likely to report earnings for its third quarter.